Abstract
In the 70-80th of last century, it has been shown that the antidiabetic biguanide drugs phenformin (PF) and buformin (BF) can exert an inhibitory action on carcinogenesis in animal models and increase from 5 to 10-years survival of cancer patients. Since 2005, after first evidence publication of the capacity of metformin (MF), another biguanide, to prevent development of malignant tumors in individuals with type 2 diabetes (T2D) and suppress tumorigenesis in mice, the burst of studies started in this field focused on breast, pancreas, prostatic, endometrial and some other cancers. Colorectal cancer (CRC) is the most prevalent among digestive system cancers. In this mini-review are presented the available data on the capacity of antidiabetic biguanide drugs to prevent colorectal carcinogenesis and growth in vitro and in vivo in experimental models and clinical observations.
Keywords: Colorectal cancer, metformin, prevention, treatment.
Current Drug Targets
Title:Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data
Volume: 17 Issue: 4
Author(s): Vladimir N. Anisimov
Affiliation:
Keywords: Colorectal cancer, metformin, prevention, treatment.
Abstract: In the 70-80th of last century, it has been shown that the antidiabetic biguanide drugs phenformin (PF) and buformin (BF) can exert an inhibitory action on carcinogenesis in animal models and increase from 5 to 10-years survival of cancer patients. Since 2005, after first evidence publication of the capacity of metformin (MF), another biguanide, to prevent development of malignant tumors in individuals with type 2 diabetes (T2D) and suppress tumorigenesis in mice, the burst of studies started in this field focused on breast, pancreas, prostatic, endometrial and some other cancers. Colorectal cancer (CRC) is the most prevalent among digestive system cancers. In this mini-review are presented the available data on the capacity of antidiabetic biguanide drugs to prevent colorectal carcinogenesis and growth in vitro and in vivo in experimental models and clinical observations.
Export Options
About this article
Cite this article as:
Anisimov N. Vladimir, Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data, Current Drug Targets 2016; 17 (4) . https://dx.doi.org/10.2174/1389450116666150309113305
DOI https://dx.doi.org/10.2174/1389450116666150309113305 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mutation Mechanisms of Breast Cancer among the Female Population in China
Current Bioinformatics Has Selenium a Chemopreventive Effect on Hepatocellular Carcinoma?
Mini-Reviews in Medicinal Chemistry From Systems Biology to Systems Pathology: A New Subspecialty in Diagnostic and Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome
Current Genomics Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets Optimizing Anti-EGFR Strategies in Cancer Treatment
Current Cancer Therapy Reviews subject Index To Volume 5
Combinatorial Chemistry & High Throughput Screening Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Flavonoids as Prospective Aromatase Inhibitors in Breast Cancer Prevention/ Therapy
Current Molecular Pharmacology Mechanism of Action and Therapeutic Potential of Novel Adamantyl Retinoid-Related Molecules
Current Cancer Therapy Reviews Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Oncogene-Directed Therapies as Modulators of Cancer Coagulopathy, Angiogenesis and Tumor-Vascular Interface
Current Signal Transduction Therapy Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease
Current Topics in Medicinal Chemistry Impairment of Lung Function During Adjuvant Oxaliplatin Treatment in Patients with Colorectal Cancer: A Prospective Trial
Current Drug Safety The Role of Diet Related Short-Chain Fatty Acids in Colorectal Cancer Metabolism and Survival: Prevention and Therapeutic Implications
Current Medicinal Chemistry Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
Current Pharmaceutical Design An Update on Developments in Female Hormonal Contraception
Current Women`s Health Reviews Editorial (Hot Topic: Bioinformatics and Quantitative Structure-Property Relationship (QSPR) Models)
Current Bioinformatics